Medivir AB, the pharmaceutical company that focuses on developing high-value treatments for infectious diseases and its
development partner, Tibotec Pharmaceuticals, have entered into an agreement with Bristol-Myers Squibb Company
for the treatment of genotype-1 chronic hepatitis C virus infection.
“We are very excited to work with Bristol-Myers Squibb to investigate our protease inhibitor,
TMC435, in combination with an NS5A replication complex inhibitor to enable the
advancement of novel treatment options for people chronically infected with HCV. We
believe that an all oral, treatment regimen for HCV would represent a major step towards
improved HCV treatments.” – Charlotte Edenius Executive VP Research & Development
TMC435 has received “Fast Track” designation by the U.S. Food and Drug Administration
for the treatment of chronic hepatitis C (CHC) genotype-1 infection. TMC435 is
currently being developed in three global phase III studies, QUEST-1 and QUEST-2 in
treatment-naive patients and PROMISE in patients who have relapsed after prior
interferon-based treatment. In parallel with these trials, phase III studies for TMC 435 in
Japan are ongoing for both treatment-naive and treatment-experienced hepatitis C genotype-1 infected
patients.
